Overcoming Limitations and Barriers Associated with Treating Pulmonary Arterial Hypertension

EP: 1.Evolving Guidelines for PAH Treatment

EP: 2.New Therapeutic Frontiers in PAH

EP: 3.Addressing Unmet Needs and Disease Progression Challenges in Pulmonary Arterial Hypertension Management

Now Viewing

EP: 4.Overcoming Limitations and Barriers Associated with Treating Pulmonary Arterial Hypertension

EP: 5.Breaking Down the PAH Cost Burden

EP: 6.A New Era in PAH Treatment?

EP: 7.Clinical Evidence for Emerging PAH Therapies

EP: 8.Integrating New PAH Therapies into Clinical Practice

EP: 9.Optimizing Complex Pulmonary Arterial Hypertension Care: Enhancing Adherence and Outcomes

EP: 10.FDA Approves Sotatercept for Pulmonary Arterial Hypertension

EP: 11.Overcoming Barriers to Better Patient Outcomes in PAH

EP: 12.Advancing Pulmonary Arterial Hypertension Care: Overcoming Challenges in Special Populations and Exploring Innovative Approaches

EP: 13.Optimizing PAH Care Delivery for Better Outcomes

EP: 14.Addressing Unmet Needs in the PAH Landscape

Video content above is prompted by the following questions:

• What are the limitations of current pulmonary arterial hypertension (PAH) therapies that primarily focus on symptom management, and how do they impact patient outcomes?
• How does the high disease burden associated with PAH affect patients' quality of life and functional status?
• What are the barriers to early diagnosis and initiation of treatment for PAH, and how do they contribute to poor outcomes?